Vaccine Info

Menveo Meningococcal Vaccine

Authored by
Staff
Last reviewed
March 6, 2022
Fact checked by
Robert Carlson, MD
Share

Menveo Vaccine Description For 2022

Menveo consists of two portions: 10 µg of lyophilized meningococcal serogroup A capsular polysaccharide conjugated to CRM197 and 5 μg each of capsular polysaccharide of serogroup C, W, and Y conjugated to CRM197 in 0.5 mL of phosphate-buffered saline, which is used to reconstitute the lyophilized MenA component.

Menveo Vaccine Indication

Menveo is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. 

Menveo does not prevent N. meningitidis serogroup B infections.

CDC recommends MenACWY vaccination for children who are between 2 months and 10 years old if they:

  • Have a rare type of immune disorder called complement component deficiency
  • Are taking a type of medicine called a complement inhibitor (for example, Soliris® or Ultomiris®)
  • Have a damaged spleen or sickle cell disease, or their spleen has been removed
  • Have HIV
  • Are traveling to or residing in countries in which serogroup A, C, W, or Y meningococcal disease is common
  • Are part of a population identified to be at increased risk because of a serogroup A, C, W, or Y meningococcal disease outbreak

All 11 to 12-year-olds should get a MenACWY vaccine, with a booster shot at 16 years old.

Menveo Vaccine Dosage

Menveo is administered as an intramuscular injection. Menveo is approved for use in persons 2 months through 55 years of age: In children initiating vaccination at 2 months of age, Menveo is to be administered as a 4-dose series at 2, 4, 6, and 12 months of age. 

In children initiating vaccination at 7 months through 23 months of age, Menveo is to be administered as a 2-dose series with the second dose administered in the second year of life and at least 3 months after the first dose.

In individuals, 2 years through 55 years of age MENVEO is to be administered as a single dose. 

Menveo Vaccine News 2022

February 9, 2022 - GSK reported during 2021, Menveo sales were up 3% AER 9% CER to £272 million, primarily driven by 2020 cohort catch-up vaccinations and 2021 higher demand, as well as increased market share in the US.

Menveo Clinical Trials

GSK's Menveo has been involved in many clinical trials.  

Clinical Trials

No clinical trials found